Results 11 to 20 of about 70 (55)

Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease [PDF]

open access: yes, 2023
Alzheimer's disease (AD) is the most common cause of dementia worldwide. According to the widely accepted theory, it is caused by neurodegeneration initiated by the deposition of a pathological protein, amyloid β, in the brain. Amyloid β can aggregate to
Jakub Wojcieszak
core   +1 more source

Treatment of obsessive-compulsive disorders (OCD) and obsessive-compulsive-related disorders (OCRD) [PDF]

open access: yes, 2019
The purpose of this article is to present an overview of current knowledge on the treatment of obsessive-compulsive and obsessive-compulsive-related disorders (OCRD - according to DSM-5).
Krzanowska, Eliza   +2 more
core   +1 more source

Understanding obsessive-compulsive disorder - literature review [PDF]

open access: yes, 2023
Introduction: Obsessive-compulsive disorder can decrease the quality of life and is often experienced by patients throughout their lives. They involve the presence of obsessions (persistent, unwanted thoughts) and compulsions (actions/rituals performed ...
Ciechański, Marcin   +9 more
core   +1 more source

Kliniczne aspekty stosowania memantyny w monoterapii i politerapii choroby Alzheimera [PDF]

open access: yes, 2013
Memantyna, niekompetycyjny antagonista kwasu N-metylo--D-asparaginowego, została zarejestrowana przez agencjeregulujące rynek leków (Food and Drug Administration, EuropeanMedicines Agency, National Institute for Health andClinical Excellence) w leczeniu ...
Sobów, Tomasz
core   +4 more sources

Current state of knowledge concerning experimental applications for deep brain stimulation in specific neurologic and psychiatric disorders [PDF]

open access: yes, 2022
Introduction and objectives. Deep brain stimulation  (DBS) is an invasive treatment method of certain neurologic and psychiatric disorders. It relies on sending external electrical stimulus to specific targets within the brain, causing change in ...
Doruch, Patrycja   +2 more
core   +1 more source

The use of SGLT2 inhibitors in the treatment of cognitive disorders [PDF]

open access: yes, 2023
Background:Dementia is a progressive and irreversible disease entity that affects memory, verbal fluency, thinking and the performance of daily activities.The most common type of dementia is alzheimer's disease(AD).Currently, there are no specific ...
Antonik, Dominika   +9 more
core   +1 more source

Kliniczne znaczenie blokowania receptora NMDA [PDF]

open access: yes, 2013
Teoria ekscytotoksyczności jako jednego z istotnych mechanizmówuszkodzenia komórek układu nerwowego przyczyniła siędo badań nad rolą aminokwasów pobudzających i receptorówNMDA w patogenezie schorzeń neurozwyrodnieniowych, zespołówpourazowych, w przebiegu
Sławek, Jarosław
core   +1 more source

Pharmacotherapy of neuropathic pain [PDF]

open access: yes, 2017
Ból neuropatyczny stanowi istotny problem ze względu na częstość występowania i trudności w zapew­nieniu skutecznego leczenia. Wśród chorych na nowotwory komponent neuropatyczny bólu jest częsty, między innymi z powodu zmian w układzie nerwowym u ...
Leppert, Wojciech   +2 more
core   +4 more sources

Zasady postępowania terapeutycznego w zespołach otępiennych [PDF]

open access: yes, 2007
Mimo znacznych postępów w rozumieniu etiopatogenezy otępień, zwłaszcza w przebiegu choroby Alzheimera, dotąd nie opracowano skutecznych metod leczenia, oferując lekarzom i ich pacjentom jedynie ograniczone działanie objawowe.
Sobów, Tomasz
core   +1 more source

Alzheimer's disease - a review of medicinal substances and their derivatives [PDF]

open access: yes
Alzheimer’s disease (AD) is a neurodegenerative disorder. Although the first case of Alzheimer’s disease was recorded over a century ago, the etiology of the disease remains unknown. There are several hypotheses regarding the process of neurodegeneration,
Dorota G. Piotrowska   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy